These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9462722)

  • 1. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
    Samuel J; Budzynski WA; Reddish MA; Ding L; Zimmermann GL; Krantz MJ; Koganty RR; Longenecker BM
    Int J Cancer; 1998 Jan; 75(2):295-302. PubMed ID: 9462722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
    Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
    Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
    Sarkar S; Salyer AC; Wall KA; Sucheck SJ
    Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.
    Yang M; Yan Y; Fang M; Wan M; Wu X; Zhang X; Zhao T; Wei H; Song D; Wang L; Yu Y
    Int Immunopharmacol; 2012 Aug; 13(4):408-16. PubMed ID: 22595192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.
    Du JJ; Zou SY; Chen XZ; Xu WB; Wang CW; Zhang L; Tang YK; Zhou SH; Wang J; Yin XG; Gao XF; Liu Z; Guo J
    Chem Asian J; 2019 Jun; 14(12):2116-2121. PubMed ID: 31042017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
    Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
    Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
    Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
    Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
    Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response.
    Zhang H; Jia E; Xia W; Lv T; Lu C; Xu Z; Zhu W
    Vaccine; 2019 Apr; 37(15):2090-2098. PubMed ID: 30837171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs.
    Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X
    Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1).
    Johnen H; Kulbe H; Pecher G
    Cancer Immunol Immunother; 2001 Sep; 50(7):356-60. PubMed ID: 11676395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene.
    Ding L; Lalani EN; Reddish M; Koganty R; Wong T; Samuel J; Yacyshyn MB; Meikle A; Fung PY; Taylor-Papadimitriou J
    Cancer Immunol Immunother; 1993; 36(1):9-17. PubMed ID: 8422670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
    Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
    Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.
    Apostolopoulos V; Pietersz GA; Loveland BE; Sandrin MS; McKenzie IF
    Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10128-32. PubMed ID: 7479739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine.
    Hu B; Wang J; Guo Y; Chen T; Ni W; Yuan H; Zhang N; Xie F; Tai G
    Int Immunopharmacol; 2016 Apr; 33():108-18. PubMed ID: 26896668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice.
    Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM
    Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy.
    Guo M; You C; Dong W; Luo B; Wu Y; Chen Y; Li J; Pan M; Li M; Zhao F; Dou J
    Biomed Pharmacother; 2020 Dec; 132():110804. PubMed ID: 33017767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.